In mouse experiments, the TRPM8 antagonist M8-B hydrochloride exhibited potential in inhibiting the activation of cholangiocytes by downregulating the expression of inflammatory factor S100A9 and upregulating the expression of HNF4α, which ultimately led to the amelioration of hepatobiliary inflammation and liver fibrosis [46]. The gene discussed is TRPM8; the disease is Hepatic fibrosis.